Is Melanotan II with PT-141 legal in the United Kingdom?

Two melanocortin agonists run together, one of which is the active metabolite of the other. That is the whole problem: bremelanotide is what melanotan II becomes in the body, so this is one drug class hit twice, with the pigment-inducing parent and its approved metabolite in the same session. Vial sizes are not consistent and the combination has never been studied.

Bremelanotide, sold as PT-141, is a metabolite of melanotan II. That relationship is the reason both exist and it is the reason stacking them makes very little pharmacological sense.

Mechanism: Both are non-selective melanocortin receptor agonists. Bremelanotide acts largely through melanocortin 4 receptor signalling in the central nervous system, which is the sexual desire pathway.

Regulatory history: Bremelanotide is FDA approved for hypoactive sexual desire disorder in premenopausal women. Melanotan II is not approved anywhere and has been the subject of regulator warnings in several countries.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Melanotan II with PT-141 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.